Topic: smart inhaler

Boehringer Ingelheim has invested €225 million on inhaler production with a new plant in Spain and expanded lines in Germany.

As patients continue taking a more active role in healthcare, pharma's interest in digital therapeutics, already on a roll, will only accelerate.

If you've been following pharma's “smart inhaler” deals, you might think the industry's up to speed on sensor tech—but you'd be wrong.

GlaxoSmithKline is again having manufacturing issues with some of its inhalers, leading it to voluntarily recall products in markets outside the U.S.
 

The race for the respiratory tech lead is on, and Boehringer Ingelheim is the latest to surge forward.

Respiratory player Vectura can set aside its hopes of snagging a COPD indication for ICS/LABA med Flutiform--at least, for now.

Not enough drugmakers on the “smart inhaler” bandwagon for you? Well, go ahead and add AstraZeneca to the list.

Pharma companies are discovering that developing apps and digital health technologies is just like developing drugs--at least when it comes to persuading payers to cover them.

There’s yet another respiratory drugmaker jumping on the “smart inhaler” bandwagon--and that’s the U.K.’s Vectura.

Crystal Lake, Illinois-based Aptar Pharma launched technology designed to monitor dosing and adherence in its inhalers. It also teamed up with Adapt Pharma to provide a nasal spray device to reverse opioid overdose, also using metered dosing technology.